Investors

Recent Releases

September 15, 2026

Media Advisory: Emergent to Host Ribbon Cutting Ceremony at Canton Manufacturing Facility

Company leaders, elected officials and community stakeholders will come together on September 16, 2026 to mark milestone in advanced biopharmaceutical manufacturing CANTON, Mass., Sept. 15, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) will host a ribbon cutting ceremony on

September 3, 2026

Emergent BioSolutions Completes Repurchase of $75 Million Aggregate Principal Amount of Senior Unsecured Notes

Repurchase reduces unsecured note balance to approximately $364.7 million Management to discuss this key milestone and broader transformation progress at upcoming investor conferences GAITHERSBURG, Md., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc.

September 1, 2026

Emergent BioSolutions Awarded Contract Modification Valued at Approximately $24 Million for CYFENDUS® (Anthrax Vaccine Adsorbed, Adjuvanted)

GAITHERSBURG, Md., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced a contract modification valued at approximately $24 million from the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and